Company to showcase its innovative
Alzheimer's, Parkinson's and ALS programs
TORONTO and CAMBRIDGE, MA, Sept. 3,
2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN)
(OTCQB: ARFXF), a biotechnology company focused on the discovery
and development of antibody therapeutics targeting toxic oligomers
implicated in the development of neurodegenerative diseases, today
announced its participation in the 21st Annual Global
Investment Conference sponsored by H.C. Wainwright & Co.
LLC. The conference is being held September 8-10, 2019 at the New York Palace Hotel
in New York.
ProMIS' Executive Chairman, Eugene
Williams will provide overviews of its novel drug discovery
and development programs for Alzheimer's disease, Parkinson's
disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at
10:25 am ET. The audio webcast
and slides of Mr. Williams' presentation will be archived and
available on ProMIS' web site and through the following link
http://wsw.com/webcast/hcw5/arfxf/.
About ProMIS' Platform Technology
Numerous studies
show that a common root cause of neurodegenerative diseases is the
toxic oligomer, a misfolded protein that derives from naturally
occurring proteins in the brain. Using its novel drug discovery
platform, ProMIS can uniquely and selectively target the toxic
oligomer, filling a critical gap for drug developers as traditional
approaches to developing antibodies are unable to isolate and
target the toxic oligomer with adequate precision. This proprietary
platform can identify targets to produce, test and advance antibody
candidates quickly and cost-effectively. ProMIS' lead candidate
antibody, PMN310 for Alzheimer's disease (AD), demonstrates a high
degree of binding to toxic oligomers without binding to non-toxic
forms of naturally occurring amyloid beta protein. The company's
program for Parkinson's disease (PD) is based on the development of
several potential antibody therapeutic candidates aimed at
selectively targeting toxic oligomers of the protein α-synuclein,
considered a root cause of PD. Similarly, ProMIS has identified
antibody candidates selectively targeting toxic oligomers of the
protein TDP43, considered a root cause of ALS.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines - ProMIS and Collective Coordinates - to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
To learn more, visit us at www.promisneurosciences.com, follow
us on Twitter and LinkedIn and listen to the podcast, Saving
Minds, at iTunes or Spotify.
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-to-present-at-hc-wainwright-investment-conference-300909802.html
SOURCE ProMIS Neurosciences Inc.
